Diagnostic Imaging and Laboratory Services in the US

Diagnostic imaging and laboratory services form the investigative backbone of American medicine — the point where a physician's clinical suspicion meets hard evidence. From a routine blood panel ordered at a primary care visit to an MRI that catches a tumor before symptoms appear, these services generate the data that drives nearly every significant treatment decision. Understanding how they work, who pays for them, and where the lines between necessary and discretionary testing are drawn is essential context for anyone navigating the US healthcare system.

Definition and scope

Diagnostic imaging encompasses any technology that produces visual representations of the body's interior — X-ray, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, positron emission tomography (PET), and nuclear medicine scans among them. Laboratory services cover the analysis of biological specimens: blood, urine, tissue, saliva, and cerebrospinal fluid, processed to detect disease markers, measure organ function, identify pathogens, or assess genetic risk.

Together, these two service categories touch an extraordinary share of patient encounters. The Centers for Medicare and Medicaid Services (CMS) reports that clinical laboratory fee schedule services represent billions in annual Medicare expenditure, with Part B laboratory claims alone reaching approximately $8 billion per year (CMS Clinical Laboratory Fee Schedule). Imaging services carry similar weight: the Medicare Payment Advisory Commission (MedPAC) has flagged advanced imaging — particularly CT and MRI — as one of the consistently high-volume, high-cost segments of outpatient spending.

These services sit within the broader architecture of specialty care and preventive care and screenings, though they are ordered by providers across virtually every specialty.

How it works

The typical pathway runs in four stages:

1. Order placement — A licensed provider (physician, nurse practitioner, or physician assistant) issues a written or electronic order based on clinical indication. Most insurers require documented medical necessity; without it, the claim may be denied or the patient billed at full cost.
2. Facility or lab selection — The patient goes to a hospital-based imaging center, a freestanding radiology practice, a physician office lab, or an independent laboratory such as Quest Diagnostics or Labcorp. This choice has direct cost implications — hospital-based imaging frequently carries a facility fee that freestanding centers do not.
3. Service performance and interpretation — The scan is performed by a technologist (radiologic technologist, sonographer, nuclear medicine technologist) and then interpreted by a radiologist or pathologist who generates a formal report. That report, not the raw image, is the clinical deliverable.
4. Result transmission and follow-up — Results flow back to the ordering provider, who communicates findings and next steps to the patient. Under the 21st Century Cures Act, patients have a legal right to access their diagnostic reports directly through patient portals without delay (Office of the National Coordinator for Health IT, Cures Act Final Rule).

A meaningful distinction exists between in-network and out-of-network providers. A patient whose physician is in-network may unknowingly receive imaging or lab services from an out-of-network radiologist or reference laboratory, triggering surprise billing — a problem the No Surprises Act (effective January 2022) partially addressed for emergency settings but left more loosely regulated in scheduled outpatient contexts.

Common scenarios

The situations where imaging and laboratory services get ordered range from the completely routine to the urgently diagnostic:

• Annual wellness visits typically include metabolic panels, lipid profiles, and complete blood counts — the workhorses of preventive medicine.
• Emergency presentations like chest pain or head trauma trigger immediate imaging: chest X-ray, CT of the head or chest, or electrocardiogram-guided cardiac enzyme labs.
• Chronic disease management relies heavily on serial lab testing. A patient with Type 2 diabetes may receive hemoglobin A1c testing every 3 months, renal function panels twice yearly, and periodic urine microalbumin screening.
• Cancer screening and staging uses mammography, low-dose CT for lung cancer in high-risk smokers (recommended for adults aged 50–80 with a 20 pack-year smoking history, per the US Preventive Services Task Force), PET-CT for staging known malignancies, and tissue biopsy with pathological analysis.
• Pre-surgical workup assembles a baseline picture of organ function — coagulation studies, renal panel, type and screen — before any procedure requiring anesthesia.

Decision boundaries

Not every scan a patient wants — or a physician might reflexively order — clears the threshold of clinical necessity, and that line is policed in at least three ways.

Payer preauthorization is the most visible mechanism. Most commercial insurers and Medicare Advantage plans require prior authorization for advanced imaging (MRI, CT, PET). Beginning in 2020, CMS implemented the Appropriate Use Criteria (AUC) program under the Protecting Access to Medicare Act of 2014, requiring ordering physicians to consult clinical decision support tools before ordering advanced imaging for Medicare patients (CMS AUC Program).

Clinical guidelines establish evidence-based thresholds. The American College of Radiology publishes ACR Appropriateness Criteria — a freely searchable database rating imaging options for hundreds of clinical scenarios from "usually appropriate" to "usually not appropriate."

Radiation exposure creates a physiological decision boundary unique to imaging. CT scans deliver ionizing radiation measured in millisieverts (mSv); a single abdominal CT delivers roughly 8 mSv, compared to 0.1 mSv for a standard chest X-ray. Cumulative exposure is a legitimate clinical consideration, particularly in pediatric patients and anyone undergoing repeated imaging for chronic disease management or cancer surveillance.

The cost dimension intersects all of these. Imaging and lab costs vary dramatically by site of service and healthcare coverage options — a dynamic tracked in detail through federal healthcare price transparency requirements that took effect for hospitals in 2021 and for insurers beginning in 2022. Patients with uninsured or underinsured status face the starkest exposure, often billed chargemaster rates that bear little relationship to negotiated insurance prices.